I2536

ICI 192605

≥98% (HPLC)

• Synonym(e): (4Z)-rel-, 4(Z)-6-(2-o-chlorophenyl-4-o-hydroxyphenyl-1,3-dioxan-cis-5-yl) hexenoic acid, 4-Hexenoic acid, 6-[(2R,4R,5S)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]-
• Empirische Formel (Hill-System): C₂₂H₂₃ClO₅
• CAS-Nummer: 117621-64-4
• Molekulargewicht: 402.87
• MDL-Nummer: MFCD00673936
• UNSPSC-Code: 12352200
• PubChem Substanz-ID: 329815367
• NACRES: NA.77

Eigenschaften

• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: white to tan
• Löslichkeit: DMSO: ≥20 mg/mL
• Ersteller: AstraZeneca
• Lagertemp.: −20°C
• SMILES String: OC(=O)CC\C=C/C[C@H]1CO[C@H](O[C@H]1c2ccccc2O)c3ccccc3Cl
• InChI: 1S/C22H23ClO5/c23-18-11-6-4-9-16(18)22-27-14-15(8-2-1-3-13-20(25)26)21(28-22)17-10-5-7-12-19(17)24/h1-2,4-7,9-12,15,21-22,24H,3,8,13-14H2,(H,25,26)/b2-1-/t15-,21+,22+/m0/s1
• InChIKey: WHUIENZXNGAHQI-YGPRPMEGSA-N

Beschreibung

Biochem./physiol. Wirkung

ICI 192605 is a potent thromboxane A2 receptor antagonist. It inhibits platelet aggregation and can reverse the effects of vasoconstrictors such as TXA2 or PGD2. ICI 192605 can reverse vasoconstriction induced by inhibition of NO production by L-NEMA, which leads to an increase in TXA2 release.

Leistungsmerkmale und Vorteile

This compound is featured on the Prostanoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Piktogramme: GHS07,GHS09
• Signalwort: Warning
• H-Sätze: H302,H410
• P-Sätze: P264 - P270 - P273 - P301 + P312 - P391 - P501
• Gefahreneinstufungen: Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1
• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable